Subscribe To
GALT / Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
GALT News
By GlobeNewsWire
October 23, 2023
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin more_horizontal
By GlobeNewsWire
September 26, 2023
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target gale more_horizontal
By GlobeNewsWire
September 13, 2023
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
NORCROSS, Ga., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galecti more_horizontal
By GlobeNewsWire
September 11, 2023
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
NORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galecti more_horizontal
By GlobeNewsWire
September 7, 2023
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galecti more_horizontal
By Zacks Investment Research
August 17, 2023
What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock
Galectin Therapeutics Inc. (GALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Ran more_horizontal
By GlobeNewsWire
November 28, 2022
Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit
NORCROSS, Ga., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin more_horizontal
By Seeking Alpha
July 11, 2022
Galectin: Ability To Potentially Target Unmet Medical Need
Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without esophageal varices are expected in more_horizontal
